性激素受体及其靶向治疗在肝细胞癌中的应用前景

Sex Hormone Receptors and Targeted Therapy Application Prospects in Hepatocellular Carcinoma

肝细胞癌(HCC)是一种缺乏有效治疗手段的恶性肿瘤。它的发病与慢性肝炎相关且男性患者比例较大,说明HCC的发生具有性别差异性,显示了性激素类物质对HCC的发生起着重要的作用。当前关于性激素及其受体在HCC发生、发展中的作用研究仍然比较贫乏,使得临床上HCC激素治疗法广受争议。该文对目前可认知的雄激素受体和雌激素受体对HCC的相关作用机制进行系统性分析,同时对性激素类及其受体靶向治疗HCC的前景进行探讨。

Hepatocellular carcinoma （HCC） is one of the most lethal malignancies lack of effective treatment. The major risk factors for HCC are chronic liver diseases. HCC also has gender disparity ： a higher incidence of HCC in males suggests an important role of sex hormones in HCC pathogenesis. However,the precise function of male and female sex hormones or their receptors is still poorly understood in HCC, which makes clinical trials with hormones remain controversial. Here is to systematically integrate the mechanism information currently available on androgens, estrogens and their receptors in HCC develop- ment, and explore their potential as the target therapy in HCC treatment.